Impact of expanding nirsevimab immunoprophylaxis, extended window and catch-up, on RSV hospitalizations in infants: a three-season, multicentre, population-based study in Emilia-Romagna, Italy

Background Respiratory syncytial virus (RSV) is a major cause of hospitalization in infancy, particularly during the first months of life. Nirsevimab has substantially reduced RSV-related hospitalizations in early real-world studies, but the incremental population-level benefit of expanding an established seasonal programme to broader birth cohorts remains uncertain. In Emilia-Romagna, Italy, nirsevimab was introduced for the 2024–25 RSV season as seasonal at-birth immunoprophylaxis and expanded in 2025–26 to include at-birth immunoprophylaxis for infants born from August 2025 through March 2026 and catch-up immunization for infants born from April through July 2025. We assessed whether this expanded strategy provided an additional reduction in RSV-compatible hospitalizations. Methods We conducted a multicentre, population-based observational before–after study using hospital discharge records from eleven centres, covering approximately 69% of hospitalizations among infants aged <12 months. RSV-compatible hospitalizations were compared across three seasons: Pre-Nirsevimab (2023–24), Seasonal (2024–25), and Extended seasonal + catch-up (2025–26). Incidence rate ratios (IRRs) were estimated by negative binomial regression adjusted for sex and age. Net avoided hospitalizations were also calculated. Results Age-standardized RSV-compatible hospitalization rates declined from 21.9 per 100, 000 person-days in 2023–24 to 10.1 in 2024–25 and 7.8 in 2025–26. Compared with the Seasonal strategy, the Extended seasonal + catch-up strategy was associated with a further 22% reduction in hospitalization risk (IRR 0.78; 95% CI 0.69–0.88; p<0.001) and a 64% reduction versus Pre-Nirsevimab (IRR 0.36; 95% CI 0.31–0.42). An estimated 103.3 additional hospitalizations were avoided versus 2024–25 and 677.8 versus Pre-Nirsevimab, corresponding to approximately 52 and 339 avoided hospitalizations per 10, 000 infants, respectively. Findings were consistent in infants aged 0–180 days. Conclusions Expanding nirsevimab immunoprophylaxis was associated with a further significant reduction in RSV-compatible hospitalizations beyond that achieved with seasonal-only administration. Given the observational design, causal inference should remain cautious.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1974003
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of expanding nirsevimab immunoprophylaxis, extended window and catch-up, on RSV hospitalizations in infants: a three-season, multicentre, population-based study in Emilia-Romagna, Italy

Susanna Esposito, Angela Miniaci, Caterina Caminiti, Matteo Puntoni et al.
8 links
Frontiers in Immunology
Respiratory viral infections research
article

Impact of expanding nirsevimab immunoprophylaxis, extended window and catch-up, on RSV hospitalizations in infants: a three-season, multicentre, population-based study in Emilia-Romagna, Italy

Susanna Esposito, Angela Miniaci, Caterina Caminiti, Matteo Puntoni, Federico Marchetti, Battista Guidi, Cristina Malaventura, Alessandro De Fanti, Agnese Suppiej, Valentina Fainardi, Andrea Miceli, Gianluca Vergine, Giuseppe Maglietta, Emanuele Filice, Melodie Olivia Loredana Rosa Aricò, Giuseppe Cannalire, Chiara Ghizzi, Marcello Lanari, Giacomo Biasucci, Francesco Accomando, Marcello Stella, Francesca Alberghi, Stefano Bendoni, Gaia Giorgia Arnesano
article en

Abstract

Background Respiratory syncytial virus (RSV) is a major cause of hospitalization in infancy, particularly during the first months of life. Nirsevimab has substantially reduced RSV-related hospitalizations in early real-world studies, but the incremental population-level benefit of expanding an established seasonal programme to broader birth cohorts remains uncertain. In Emilia-Romagna, Italy, nirsevimab was introduced for the 2024–25 RSV season as seasonal at-birth immunoprophylaxis and expanded in 2025–26 to include at-birth immunoprophylaxis for infants born from August 2025 through March 2026 and catch-up immunization for infants born from April through July 2025. We assessed whether this expanded strategy provided an additional reduction in RSV-compatible hospitalizations. Methods We conducted a multicentre, population-based observational before–after study using hospital discharge records from eleven centres, covering approximately 69% of hospitalizations among infants aged <12 months. RSV-compatible hospitalizations were compared across three seasons: Pre-Nirsevimab (2023–24), Seasonal (2024–25), and Extended seasonal + catch-up (2025–26). Incidence rate ratios (IRRs) were estimated by negative binomial regression adjusted for sex and age. Net avoided hospitalizations were also calculated. Results Age-standardized RSV-compatible hospitalization rates declined from 21.9 per 100, 000 person-days in 2023–24 to 10.1 in 2024–25 and 7.8 in 2025–26. Compared with the Seasonal strategy, the Extended seasonal + catch-up strategy was associated with a further 22% reduction in hospitalization risk (IRR 0.78; 95% CI 0.69–0.88; p<0.001) and a 64% reduction versus Pre-Nirsevimab (IRR 0.36; 95% CI 0.31–0.42). An estimated 103.3 additional hospitalizations were avoided versus 2024–25 and 677.8 versus Pre-Nirsevimab, corresponding to approximately 52 and 339 avoided hospitalizations per 10, 000 infants, respectively. Findings were consistent in infants aged 0–180 days. Conclusions Expanding nirsevimab immunoprophylaxis was associated with a further significant reduction in RSV-compatible hospitalizations beyond that achieved with seasonal-only administration. Given the observational design, causal inference should remain cautious.

Frontiers in ImmunologyVol. 17
University of Parma (IT), University of Ferrara (IT), Santa Maria Nuova Hospital (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Unita' Sanitaria Locale Di Modena (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), Santa Maria Nuova Hospital (IT), Azienda Unità Sanitaria Locale Della Romagna (IT), University Hospitals Parma Medical Center (US), Ospedale G.B. Morgagni - L.Pierantoni (IT), Ospedale Infermi di Rimini (IT), Guglielmo da Saliceto Hospital (IT), Azienda Unità Sanitaria Locale Rimini (IT), University of Bologna (IT)
Università degli Studi di Parma
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon